Form 4: CYTOKINETICS CFO Sells Shares for Tax Withholding

Cytokinetics' EVP and CFO, Sung Lee, sold 1,560 shares of common stock to cover tax obligations related to vested performance stock units.

Summary

• Sung Lee, Executive Vice President and Chief Financial Officer of Cytokinetics Inc. (CYTK), reported a transaction involving the company's common stock.
• On December 3, 2025, Mr. Lee disposed of 1,560 shares of common stock at a price of $65.02 per share.
• This transaction was a 'sell to cover' for tax withholding purposes, triggered by the vesting of Performance Stock Units (PSUs) that were earned on December 2, 2024.
• Following this transaction, Mr. Lee beneficially owns 67,917 shares of Cytokinetics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax withholding purposes upon the vesting of performance stock units, which is a common practice for executives and does not inherently indicate a positive or negative outlook on the company's future.

Positives

• The transaction indicates the vesting of Performance Stock Units (PSUs), suggesting that performance conditions for these equity awards were met, which is a positive for executive compensation and retention.

Negatives

• The sale of 1,560 shares by a key executive, even for tax purposes, results in a minor reduction in direct insider ownership.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it solely reports an insider transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all industries when executives receive equity compensation that vests and triggers tax liabilities. It does not provide information relevant to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine tax-related sale by an executive and does not signal a change in company fundamentals or management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Sung Lee, CFO, Tax Withholding, Performance Stock Units